Background-The endomyocardial biopsy (EMB) is considered the gold standard in rejection surveillance post cardiac transplant, but is invasive, with risk of complications. A previous trial suggested that the gene expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 months post transplant. As most rejections occur in the first 6 months, we conducted a single-center randomized trial of GEP versus EMB starting at 55 days post transplant (when GEP is valid). Methods and Results-Sixty heart transplant patients meeting inclusion criteria were randomized beginning at 55 days post transplant to either GEP or EMB arms. A positive GEP ≥30 between 2 and 6 months, or ≥34 after 6 months, prompted a follow-up biopsy. The primary end point included a composite of death/retransplant, rejection with hemodynamic compromise or graft dysfunction at 18 months post transplant. A coprimary end point included change in first-year maximal intimal thickness by intravascular ultrasound, a recognized surrogate for long-term outcome. Corticosteroid weaning was assessed in both the groups. The composite end point was similar between the GEP and EMB groups (10% versus 17%; log-rank P=0.44). The coprimary end point of first-year intravascular ultrasound change demonstrated no difference in mean maximal intimal thickness (0.35±0.36 versus 0.36±0.26 mm; P=0.944). Steroid weaning was successful in both the groups (91% versus 95%). Conclusions-In this pilot study, GEP starting at 55 days post transplant seems comparable with EMB for rejection surveillance in selected heart transplant patients and does not result in increased adverse outcomes. GEP also seems useful to guide corticosteroid weaning. Larger randomized trials are required to confirm these findings. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00962377.
C ardiac allograft rejection is experienced by 20% to 50% of patients at least once during the first year after cardiac transplantation, with the highest incidence of acute cellular rejection occurring in the first 6 months. 1 Endomyocardial biopsy (EMB) is currently acknowledged as the gold standard in monitoring rejection status post cardiac transplantation. 2 However, EMB has potential for serious complications and is invasive and resource-intensive.
Clinical Perspective on p 564
Immediate complications of EMB can include access site hematoma, transient arrhythmias, right bundle branch block, occult pulmonary embolism, and cardiac tamponade secondary to myocardial perforation. 3 Longer-term complications include chronic tricuspid regurgitation (sometimes requiring valve replacement) and more rarely, coronary artery to right ventricular fistula. 4 Deaths as a direct consequence of EMB, although rare, have even been reported. 5 Alternative noninvasive methods of rejection surveillance have been pursued. These noninvasive methods have included echocardiography, cardiac magnetic resonance and molecular imaging, specific electrophysiological markers, and peripheral blood analysis. 6 These noninvasive tests are based on either detection of myocardial injury (myocardial edema) or upregulation of the immune system. However, none of these tests have demonstrated sufficient reliability to replace the EMB. Peripheral blood analysis seems the most promising and specific, and is the only noninvasive surveillance method recommended in the most recent International Society for Heart and Lung Transplantation (ISHLT) guidelines. 1 Gene expression profiling (GEP) with the AlloMap blood test (CareDx Inc, Brisbane, CA) is based on the analysis of peripheral blood mononuclear cell RNA with a multigene algorithm that uses 20 genes (11 informative and 9 controls) as a means of detecting rejection. The 11 informative genes are involved in T-cell activation and trafficking, natural killer cell activation, stem cell mobilization, hematopoiesis, and allo-immune recognition. The algorithm was developed using rejection and nonrejection samples characterized by biopsy to identify genes that could distinguish these sample types. The algorithm weighs the contribution of each gene and results in a score ranging from 0 to 40, with higher scores having a stronger correlation with histological rejection.
Clinical analyses found GEP to be valid from 55 days post transplant with GEP scores <34 being associated with low risk of moderate-to-severe acute cellular rejection on EMB (ISHLT Grade ≥3A/2R). 7 This resulted in negative predictive values of 98.1% in patients >2 to 6 months post transplant, 98.5% in patients 6 to 12 months post transplant, and 99.2% >1 year post transplant in stable outpatients. The results also demonstrated the viability of using GEP as a less invasive and more economical means to identify low-risk patients who might be managed without routine EMB. However, high corticosteroid doses (>20 mg) confounded the results and is the reason why GEP is valid after 55 days when corticosteroid doses are lower.
A nationwide, multi-center randomized controlled trial, known as the Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial, compared GEP with EMB. 8 This demonstrated that clinical outcome of heart transplant patients managed with GEP was noninferior to patients managed with EMB between 6 and 60 months post heart transplant. However, the value of early monitoring (before 6 months post transplant) by GEP has not been assessed in a randomized controlled study, despite evidence from multiple retrospective studies that most rejections initially occur within the first 6 months after transplantation. 1, 9, 10 Furthermore, there seems to be prognostic significance to early rejection, as it is likelier to progress to more severe rejection. 11 We therefore conducted the Early Invasive Monitoring Attenuation through Gene Expression (EIMAGE) study, a single-center randomized trial to describe the safety and efficacy of GEP in comparison with EMB in the monitoring of cardiac transplant rejection initiated from 2 to 6 months post transplant.
Methods

Study Design and Management
The EIMAGE trial is a single-center randomized parallel 2-arm interventional study conducted from 2009 to 2011 at the Cedars-Sinai Heart Institute, with the aim of comparing GEP and EMB as methods of rejection surveillance from 55 days onwards post cardiac transplant. The earlier time period post transplant differentiates it from the IMAGE trial, which had similar design, but was larger-scale and designed to test for noninferiority. 8 The trial was investigator-initiated and sponsored by CareDx Inc, the maker of the AlloMap GEP test. The investigators initiated and designed the study in collaboration with the sponsor. The trial protocol was approved by the Institutional Review Board (IRB). The sponsor was involved in the collection and source verification of the data, and the sponsor's biostatisticians performed the analyses with oversight from the study steering committee. Investigators at the core echocardiography laboratory at our institution reread all the echocardiograms to calculate the left ventricular ejection fractions (LVEFs) used in the analyses. The investigators vouch for the accuracy and completeness of the data and of all analyses.
Patients
Patients aged ≥18 years who had undergone a cardiac transplantation within the past 2 to 6 months (55-185 days) were eligible for enrollment. To minimize potential patient selection bias, consecutive potentially eligible patients were invited to participate as the patients present to clinic for routine surveillance evaluation. At the time of enrollment, patients were required to be in a clinically stable condition and to have an echocardiographic LVEF of ≥50%. Exclusion criteria included any clinical signs of declining graft function defined by symptoms of congestive heart failure at the first study surveillance visit, rejection therapy for biopsy-proven ISHLT Grade 2R (3A) or higher during the preceding 2 months, previous or current evidence of antibody-mediated rejection (AMR) defined according to the ISHLT 2004 guidelines, presence of donor-specific antibodies (DSAs), corticosteroid doses of >20 mg/d at the time of first study visit, receiving hematopoietic growth factors or blood transfusion during the previous 30 days, and pregnancy. All randomized participants provided informed written consent.
Study Procedures
Eligible patients were randomly assigned in a 1:1 ratio to either the GEP or the EMB arm for acute rejection surveillance. Monitoring for rejection with the assigned strategy was performed at prespecified intervals post transplant in both the groups according to protocol: 2 (≥55 days), 3, 4, 5, 6, 8, 10, and 12 months post transplant. The threshold for a positive GEP result was set at ≥30 for patients 2 to 6 months post transplant and ≥34 for patients after 6 months post transplant. These thresholds were based on results from the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study 7 and subsequent analyses 12 demonstrating higher sensitivity with a lower threshold in patients early post transplant. All patients in both the study arms were monitored with the use of clinical and echocardiographic assessments as per our standard of care. Patients who were selected for standardized corticosteroid weaning beginning at month 6 had their prednisone dose (baseline 5 mg daily) reduced by 1 mg/mo until completely off. These patients had monthly surveillance monitoring for acute rejection performed as per their assigned study arm during this prednisone taper off protocol. The criteria to wean patients off prednisone included those without rejection, cardiac dysfunction, multiparous females, and patients without a history of medication noncompliance. Between 12 and 18 months post transplant, rejection surveillance as per study arm was only performed if clinically indicated or to complete prednisone wean-off.
EMB outside of the scheduled visits was warranted for patients in both the groups if clinical or echocardiographic evidence of graft dysfunction was present or, in the case of the GEP arm, if the GEP score was above the specified threshold ( Figure 1 ). EMB was also performed if on routine DSA testing, performed at 3, 6, and 12 months post transplant, showed results >5000 mean fluorescence intensity. This was of importance, as GEP does not monitor for AMR. If patients had consistently elevated GEP scores and no evidence of rejection on ≥2 previous biopsies, the decision to perform a third biopsy was at the discretion of the principal investigator, taking into account the stability of the patient. If ISHLT ≥2R (3A) was found, the patient would undergo conventional treatments and return to their study arm on recovery. A summary of the study procedure is provided in Figure 1 .
An assessment of coronary artery intimal proliferation was performed using the Volcano VH intravascular ultrasound (IVUS) imaging system (Volcano Corporation, San Diego, CA) or iLab IVUS imaging system (Boston Scientific, Marlborough, MA) on study enrollment at 4 to 6 weeks post transplant (baseline) and at month 12. A minimum of 1 vessel, preferably the left anterior descending coronary artery because of its easy to access and the need to standardize, with a maximum of 3 vessels, was interrogated. The tapes were evaluated by a trained reviewer blinded to study arm assignment. IVUS was performed using an automated, mechanical pullback through the imaged vessel(s) at a rate of 0.5 mm/s. Starting at a distal branch landmark matched between baseline and follow-up, single frames were selected every 1 mm from the digitized pullback sequence and ending at a matched proximal branch or aorto-ostial landmark. For each of the selected frames, the lumen and external elastic membrane crosssectional areas were measured. The IVUS coprimary end point was prospectively defined to include patients who had a minimum of 11 matched slices from IVUS images from baseline and from the month 12 visit without missing data. Exclusion criteria for IVUS included patients in whom intravenous contrast was contradicted because of renal dysfunction (creatinine >2.0 mg/dL or >1.7 mg/dL for diabetic patients), patients with advanced cardiac allograft vasculopathy or anomalous coronary trees in whom IVUS was contraindicated and patients who did not provide written informed consent.
Outcomes
The primary outcome was a composite of first occurrence of death/ retransplant, rejection with hemodynamic compromise, or allograft dysfunction because of other causes ≤18 months post transplant.
Hemodynamic compromise was defined as the presence of ≥1 of the following: an absolute echocardiographic LVEF ≤40% or a proportional drop in LVEF of ≥25% compared with the baseline value at visit 1, a cardiac index <2 L/min per m 2 , plus the use of inotropic drugs to support circulation. Allograft dysfunction was defined as hemodynamic compromise without histologically confirmed rejection.
In addition, there was a coprimary end point of change from baseline to 12 months of maximal intimal thickness as measured by IVUS. Secondary outcomes included the objective measurements of cardiac function by right heart catheterization at 12 months, echocardiography at 18 months, the number of rejection episodes at 18 months, number of biopsies performed and biopsy-related complications at 18 months, and corticosteroid dose weaning.
We also assessed the patients' quality of life and their satisfaction with the method of monitoring for rejection. Quality of life was assessed with the use of the Medical Outcomes Study 12-Item Flowsheet diagram of patients screened, randomized, and included in the study. *Of the 33 patients who did not meet inclusion/exclusion criteria, 1 had a history or evidence of antibodymediated rejection, 7 had donor-specific antibodies, 2 were double-organ transplants, 1 had left ventricular ejection fraction <50%, 3 expired before they could be randomized, 6 were clinically unstable, 1 was receiving hemodialysis, 1 was taking erythropoietin, 9 were health maintenance organization (HMO) patients, and 2 patients were transferred out-of-region. †Other reasons for nonenrollment include 5 patients unable to consent because of a language barrier and absence of translator. EMB indicates endomyocardial biopsy; GEP, geneexpression profiling; and IRB, Institutional Review Board.
Short Form Health Survey (SF-12). We assessed satisfaction by asking the patients, "How satisfied are you with the current method of detecting rejection?" Responses were scored on an ordinal scale that ranged from 1 (very unhappy) to 10 (very happy). We also used a separate, nonvalidated survey to assess biopsy-related patient preferences.
Statistical Analysis
Given the relatively small patient population of heart transplant centers, a single-center study of de novo heart transplant recipients could not offer adequate power to detect differences in our composite primary end point of death/retransplant, rejection with hemodynamic compromise, or allograft dysfunction, or our coprimary IVUS end point of 12-month maximal intimal thickness compared with baseline. These 2 primary end points were chosen for clinical relevance, and we include statistical analyses for descriptive purposes to highlight the feasibility of this pilot study. Mean and SD for continuous variables were calculated and compared with the use of Student t test. Numbers and proportions for categorical variables were compared with the use of Fisher exact test. The Kaplan-Meier method was used to estimate the probability of eventfree progression from the composite primary end point post transplant. The Mann-Whitney U test was used to compare nonparametric patient survey data between groups.
Results
Patients
Of 133 heart transplants from 2009 to 2011, 100 patients were approached for consent (33 patients were not approached, whereas awaiting IRB approval for protocol amendment). Of these 100 patients approached, 40 were excluded. Two declined to participate; 33 did not meet the inclusion criteria, of which 1 had a history of AMR, 7 had DSAs, 2 were double-organ transplants, 1 had LVEF <50%, 3 expired before they could be randomized, 6 were deemed clinically unstable, 1 was on hemodialysis, and 1 was on erythropoietin. Nine patients were health maintenance organization patients and 2 were due for transfer out-of-region, which made them ineligible for the study. Five patients were also excluded because of language barriers (Figure 2) . Thus, 60 patients were randomly assigned to be monitored for rejection with the use of routine EMB or with the use of GEP. The baseline characteristics of the 2 groups were not significantly different, except for the greater proportion of Asians in the biopsy group (0% versus 20%; P=0.023; Table 1 ). The interval between transplantation and randomization into the study was a mean time of 53 and 50 days post transplant in the GEP and EMB groups, respectively (P=0.719).
Primary Outcomes
The incidence of the composite primary outcome in the GEP group at 18 months post transplant was not significantly different between the GEP and EMB groups (10% versus 17%; log-rank P=0.44; Table 2 ). Kaplan-Meier event-free progression probability of the composite primary outcome did not differ significantly between groups (Figure 3 ). Overall survival was 100% in both the groups. The coprimary end point of 1-year IVUS included 41 patients with interpretable paired IVUS at baseline and 1 year (18 in GEP and 23 in EMB). Nine patients did not have paired IVUS because of contraindications at the time (right groin seroma, anomalous coronary artery tree, elevated creatinine, and patient missed appointment), whereas 10 paired IVUS records were inaccessible because of technical reasons. There was no significant difference in the average change in maximal intimal thickness between the GEP and EMB groups (0.35±0.36 mm versus 0.36±0.26 mm; P=0.944). Other IVUS parameters of plaque burden in the first year were similar in the GEP group compared with the EMB group (Table 3) .
Cardiac Function
Eighteen-month echocardiographic LVEF was not significantly different between the GEP and EMB groups (59.2±7.6% versus 57.9±7.0%; P=0.522). In addition, there was no significant difference between cardiac index (2.98 and 2.83 L/min per m 2 , respectively; P=0.413) and other cardiac hemodynamics (Table 4) at 1 year between the GEP and the EMB groups.
Rejection Episodes
The number of biopsy-proven ISHLT≥2R (3A) rejection episodes within the first 18 months post transplant was not significantly different between the GEP and EMB groups (3 versus 1; log-rank P=0.31). Of the 3≥2R (3A) rejections in the GEP group, 1 episode resulted from an elevated routine GEP, which prompted a follow-up biopsy that subsequently revealed rejection. The other 2 episodes presented in the form of hemodynamic compromise and biopsy was directly performed as per protocol, revealing rejection. With regard to grades of rejection, there was no significant difference between groups. Cardiac dysfunction without biopsy-proven rejection was numerically lower in the GEP group versus the EMB group (1 versus 4; log-rank P=0.16) at 18 months post transplant.
Frequency and Safety (Complications Rate) of Biopsy in GEP Group
In the GEP group, a total of 42 biopsies at 18 months post transplant were performed in this study, compared with 253 performed in the EMB group. The average frequency of biopsies was 1.4 biopsies per patient in the GEP group compared with 8.4 biopsies per patient in the EMB group. In the GEP group, 29 of 42 total biopsies were performed because of elevated GEP scores above the specified threshold, 4 were performed per protocol when signs, symptoms, or echocardiographic manifestations of graft dysfunction were present at the time of a clinic visit, 5 were performed as part of a follow-up assessment after treatment for rejection, and 4 were performed outside the study protocol (Table 5 ). In the EMB group, there were also 4 biopsies performed according to clinical need. With regard to ISHLT≥2R (3A) rejection, there were 3 incidences in the GEP arm (including 1 mixed rejection) and 1 in the EMB arm. There were no incidences of biopsy-proven AMR alone in either arm. No biopsies were performed because of elevated DSA (>5000 mean fluorescence intensity). There were 2 biopsy-related complications (supraventricular tachycardia and bleeding from the puncture site) in the EMB arm, compared with 0 in the GEP arm.
GEP and Corticosteroid Weaning Post Transplant
Prednisone weaning was attempted in 41 of 60 patients. Within the GEP arm, prednisone weaning was successful in 20 of 22 (91%) patients, compared with the EMB arm, in which weaning was successful in 18 of 19 (95%), with no significant difference. There was also no significant difference in average prednisone dosing between the 2 groups from day 100 onward post transplant.
Gene-Profiling and Patient Satisfaction
At 1 year, the SF-12 mental-health and physical-health summary scores were not significantly different between the 2 study arms (P=0.750 and P=0.564, respectively). However, patients in the GEP arm had a significantly increased satisfaction score (out of 10) for method of rejection surveillance at 1 year, with a median of 10 (10-10) in the GEP arm compared with 9.5 (7) (8) (9) (10) 
Discussion
In this single-center pilot study involving clinically stable heart transplant patients, the use of GEP was comparable with EMB for rejection surveillance beginning at 2 months post transplant and did not result in an increase in adverse outcomes, whereas having significantly less biopsies. In addition, patient satisfaction was higher with gene-profiling than with biopsy, reflecting patients' natural preference to avoid invasive procedures.
The composite primary outcomes of death/retransplant, rejection with hemodynamic compromise, and graft dysfunction were not increased in the GEP group compared with the EMB group. In addition, the IVUS results were not different between groups. First-year IVUS results, especially the parameter of maximal intimal thickness, have previously been demonstrated to be a surrogate marker for long-term outcomes in cardiac transplant patients. 13, 14 That there was no difference in the IVUS coprimary end point between the 2 study arms suggests that smoldering rejection (recurrent ISHLT 1B/1R rejection) was not clinically missed in the GEP arm compared with the biopsy arm, which might have resulted in long-term adverse outcomes. 15 The clinical end points used in our study were the most appropriate given the difference in rejection monitoring strategies in each study arm. For example, an alternative end point of all treated rejections would have been biased toward the group undergoing biopsies.
For the GEP group, a score <30 in the first 2 to 6 months was used to identify patients who were at low risk for rejection and in whom a biopsy was not needed. Although the use of a higher threshold may further minimize the number of biopsies needed, the results of our pilot trial suggest that a score <30 from 2 to 6 months post transplant, and <34 after 6 months post transplant, represent safe and suitable thresholds to use in clinical practice or a future clinical trial.
The GEP test is not designed to detect AMR. This did not seem to be an issue in this study as patients with biopsy-proven AMR in the first 2 months were excluded from study enrollment. In general, AMR is seen in <10% of cardiac transplant Table 4 ACR indicates acute cellular rejection; EMB, endomyocardial biopsy; and GEP, gene-expression profiling.
. A Comparison of Baseline and 1-Year Cardiac Function Assessed by Right Heart Catheterization in GEP and EMB Groups
*More than 1 reason could pertain to a given biopsy. Counts are not exclusive. †Clinically driven biopsies were performed because of clinical signs or symptoms of congestive heart failure, a decrease in left ventricular ejection fraction (LVEF) ≥25% compared with a previous measurement, LVEF ≤40%, ongoing antibodymediated rejection, or presence of donor-specific antibodies above threshold.
‡Reasons listed for off-protocol biopsies in GEP arm were large change in Allomap score, regional wall abnormality on Echo, LVEF slightly decreased, in hospital ventricular ectopy. §Patient 1 had supraventricular tachycardia during the biopsy procedure. Patient 2 had excess bleeding at the catheter puncture site.
patients. 16 As a safety net for AMR, in addition to regular clinical evaluation and echocardiography, any patient with newly detected DSAs was mandated to undergo a heart biopsy. However, this did not occur in any of the study patients.
Our study also demonstrated that GEP is safe and effective in safely guiding steroid weaning from 6 months onward in a similar way to EMB, with 20 of 22 in the GEP arm successfully weaned (91%) as compared with 18 of 19 (95%) in the EMB group. Biopsy-guided weaning has already been demonstrated to be safe and effective in separate clinical trials. 17, 18 The safety of GEP-guided steroid weaning here is validated by there being no difference in the composite safety end points (ie, no increased rate of death/retransplant/rejection with hemodynamic compromise/graft dysfunction) and similar long-term outcomes measured by IVUS between the 2 study arms.
Our study must be interpreted in the context of various limitations. We acknowledge that the study was not powered and that the small sample size leaves us unable to draw firm conclusions about noninferiority of early GEP use compared with EMB use. This study was also limited by the few primary end points experienced as only 8 patients reached the composite primary end point. However, based on the results, we feel this pilot study serves as proof of concept for a future large-scale trial.
With regard to the study population, the IMAGE trial was criticized for selection of largely low-risk patients who were after 6 months post transplant, 85% of whom were >1-year post transplant. 13 Although EIMAGE enrolled patients earlier post transplant, the inclusion criteria still selected for relatively low-risk patients who were on lower doses of corticosteroids (<20 mg), clinically stable with EF>50%, and who had demonstrated an absence of previous rejection or DSAs (a known risk factor for subsequent poor outcomes). Given that a noninvasive surveillance strategy is unproven with previous randomized controlled outcomes studies in patients this early post transplant, our study reflects a conservative approach toward the management of these patients. The selection of low-risk patients partially accounts for the high proportion of excluded patients (40 of 100 approached, of which 22 were excluded for clinical reasons and 18 for logistical reasons), which limits the applicability of our results. Certainly, these limitations should be acknowledged by clinicians who wish to consider GEP for rejection surveillance in their patients starting from 55 days post heart transplant. In addition, as GEP does not detect AMR, biopsy remains the only method to definitively exclude this diagnosis if suspicion is high.
In conclusion, this pilot study suggests that beginning at 55 days post cardiac transplant that the GEP blood test seems to be a safe and effective alternative to routine biopsies to monitor cardiac transplant rejection in selected patients with early favorable clinical courses. GEP also seems to be useful in the guidance of corticosteroid weaning post transplant. Further large-scale clinical trials to confirm these findings are required. 
